Viatris announced plans to acquire Pacira BioSciences in a $1.65 billion deal, aiming to expand its portfolio with Pacira’s specialty offerings. The all-shares transaction values Pacira common stock at $36.50 per share in cash. M&A in biopharma often signals a strategic shift in near-term product mix and commercial leverage, and this transaction is positioned to increase scale in pain and acute-care categories where differentiation, hospital formulary access, and supply reliability can be decisive. For investors and competitors, the deal can also shift R&D priorities and integration planning timelines, affecting how capital is allocated across Pacira’s pipeline and how Viatris manages overlapping therapeutic areas.